Summary: CBC Radio airs High Culture, Part 1 of a three-part podcast series covering the reemergence of psychedelic research for therapeutic use, featuring MAPS Founder and Executive Director Rick Doblin, Ph.D., along with Erika Dyck, Anthony Bossis, Bill Richards, and Lou Luckas.
Originally appearing here.
LSD. MDMA. Magic Mushrooms. The demonized drugs of the 1960’s, some of them banned over four decades ago, are back. But now they’re on the front-lines of medicine, as scientists around the world explore their healing properties. LSD for alcoholism. Psilocybin (magic mushrooms) for anxiety. MDMA (Ecstasy) for Post-Traumatic Stress Disorder. IDEAS producer Mary O’Connell takes a trippy path into the world of hallucinogens. Turn on, tune in, and heal thyself! Part 2 airs Thursday, October 29. Part 3 airs Tuesday, November 24.
Right now, we’re witnessing a renaissance around the world with psychedelic drugs. Clinical trials are testing psychedelics to curb anxiety, alcoholism, depression; help autistic adults become more pro-social, and enhance the mystical experience for all users — the list goes on. It all began in the 1950’s, when LSD and psilocybin (the active ingredient in magic mushrooms) were studied for their therapeutic benefits. Some of the research hot-spots included Prague, London, Boston and the unlikely town of Weyburn, Saskatchewan.
Psychiatrist Humphry Osmond was a transplant from England to Saskatchewan. The charismatic renegade had little respect for the traditional tools of his trade like psychoanalysis or electro-shock. So Osmond and his team eventually attained 50 – 90% success rates using LSD-assisted therapy for alcoholics — putting Canada on the map for psychedelic psychiatry. It was also Osmond who coined the word “psychedelic”.
But in the early 1960’s, drugs like LSD and psilocybin found their way out of university labs and onto the street — and their value as medicine was lost as their status as protest and party drugs emerged. Mass recreational use, conservative political forces and a continuing media frenzy ensured the vilification of hallucinogens – until drugs like LSD and magic mushrooms were completely outlawed in 1970. Serious medical research would not begin again until the early 21st century, four decades later.
Participants in this episode:
Erika Dyck, Professor of History, University of Saskatchewan, Canada Research Chair in Medical History.
Dr. Anthony Bossis, Clinical Assistant Professor of Psychiatry, New York School of Medicine, Co-principal investigator, NYU Psilocybin Cancer Research Project.
Rick Doblin, Founder and Executive Director of MAPS, the Multidisciplinary Association for Psychedelic Studies.
Bill Richards, Psychologist, Department of Psychiatry, Johns Hopkins University School of Medicine, Bayview Centre, Director of Clinical Work, Psilocybin Project.
Lou Lukas is a volunteer in Johns Hopkins University Psilocybin Project.